Search

Displaying results 9371 - 9380 of 9687 in total
  1. Drug

    GSK-269962A

    go.drugbank.com/drugs/DB17030
    Experimental

    GSK-269962A is a Rho kinase (ROCK) inhibitor with both ROCK1 and ROCK2 affinity.[A253012]

  2. Drug

    Homidium

    go.drugbank.com/drugs/DB17031
    Investigational

    Homidium is a group II compound with trypanocidal effects.[A253017]

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Nutlin-3

    go.drugbank.com/drugs/DB17039
    Experimental

    Nutlin-3 is a small molecule inhibitor that targets p53-Mdm2 interaction.[A253057]

  4. Drug

    PHA-767491

    go.drugbank.com/drugs/DB17043
    Investigational

    PHA-767491 is a Cdc7/CDK9 inhibitor.[A253077]

  5. Drug

    Phenylmercuric acetate

    go.drugbank.com/drugs/DB17044
    Experimental

    Phenylmercuric acetate is an organomercurial compound used as a fungicide and slimicide.[A253082]

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Pristimerin

    go.drugbank.com/drugs/DB17049
    Experimental

    Pristimerin is a quinone methide triterpenoid researched for its anti-cancer potential.[A253107]

  7. Drug

    TPCA-1

    go.drugbank.com/drugs/DB17058
    Experimental

    TPCA-1 is a selective inhibitor of human IκB kinase 2 (IKK-2).[A253152]

  8. Drug

    Sepantronium

    go.drugbank.com/drugs/DB17062
    Investigational

    Sepantronium is a compound that suppresses survivin expression in a dose and time-dependent manner, and causes broad-range apoptosis.[A253167]

  9. Drug

    JNJ-17216498

    go.drugbank.com/drugs/DB17087
    Investigational

    JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.[A253997]

  10. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]